There is a newer version of this record available.

Working paper Open Access

Ivermectin for Covid-19

Sparavigna, Amelia Carolina

Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="" xmlns:oai_dc="" xmlns:xsi="" xsi:schemaLocation="">
  <dc:creator>Sparavigna, Amelia Carolina</dc:creator>
  <dc:description>Discussion of scholar papers published until June 28, 2020,  on Ivermectin, and of news that we can find about its use for Covid-19.  A list of clinical trials is also given. For what concerns scholar papers, we report among them a preprint posted on 10 June in MedRχiv,  which concludes that Ivermectin was associated with lower mortality during treatment of Covid-19.  From news, we consider in particular the case of Iquitos,  capital city of the Loreto Region in Peru, where, by May 25, Covid-19 cases and deaths had dropped notably. </dc:description>
  <dc:description>Before reading this work, please consider that I am not a physician. I do not suggest the use of ivermectin. I am not touting this drug. This analysis of publications and news about ivermectin is made in the framework of a wider investigation about information concerning drugs used for Covid-19.</dc:description>
  <dc:title>Ivermectin for Covid-19</dc:title>
All versions This version
Views 3,929656
Downloads 1,349377
Data volume 348.3 MB81.2 MB
Unique views 3,216564
Unique downloads 1,121342


Cite as